Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23861292 | 0.71 | KMT2A (0.84) | KMT2ALMNANPSR1ALDH1A1TSHR | |
| SCHEMBL11015380 | 0.70 | KMT2A (0.81) | KMT2ANPSR1ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL29043353 | 0.68 | KMT2A (0.84) | KMT2ALMNANPSR1ALDH1A1TSHR | |
| SCHEMBL994568 | 0.67 | DGAT1 (0.33) | — | |
| SCHEMBL8313919 | 0.67 | — | — | |
| SCHEMBL11319056 | 0.65 | KMT2A (0.55) | KMT2ALMNANPSR1ALDH1A1TSHR | |
| SCHEMBL19198662 | 0.64 | THRB (0.48) | KMT2ALMNANPSR1THRBALDH1A1 | |
| SCHEMBL6152527 | 0.64 | KMT2A (0.81) | KMT2ALMNANPSR1ALDH1A1MEN1 | |
| SCHEMBL2143309 | 0.64 | KMT2A (0.53) | KMT2ALMNANPSR1ALDH1A1KDM4E | |
| SCHEMBL27906279 | 0.64 | KMT2A (0.53) | KMT2ANPSR1ALDH1A1MEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288262-B1 | Composition comprising a cyclohexane-based compound, compound and use of said compound to structure a composition | L'OREAL S.A. (FR) | 2007-10-30 | — | — | US | disclosed |
| US-6726915-B2 | DIAMIDE COMPOUNDS RETAINING GOOD COSMETIC PROPERTIES, IN PARTICULAR A CERTAIN LEVEL OF | L'OREAL (FR) | 2004-04-27 | — | — | US | disclosed |
| US-20030129211-A9 | Cosmetic or pharmaceutical composition in solid form comprising bis-acyl-amides | L'OREAL S.A. (FR) | 2003-07-10 | — | — | US | disclosed |
| US-20020150602-A1 | Cosmetic or pharmaceutical composition in solid form comprising bis-acyl-amides | LIVOREIL AUDE (FR) | 2002-10-17 | — | — | US | disclosed |
| EP-1068854-A1 | Solid form composition comprising an oil and a specific gelling agent, process for cosmetic treatment and use of this compound | L'OREAL (FR) | 2001-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030129211-A9 | Cosmetic or pharmaceutical composition in solid form comprising bis-acyl-amides | FAAH, HRH1, HRH4 | KMT2A 875/4885LMNA 2522/4885NPSR1 455/4885 |
| US-20020150602-A1 | Cosmetic or pharmaceutical composition in solid form comprising bis-acyl-amides | FAAH, HRH1, HRH4 | KMT2A 875/4885LMNA 2522/4885NPSR1 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.